😴Sleep & Recovery

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and obesity management, with cardiovascular and neuroprotective benefits.

An mTOR inhibitor gaining popularity in longevity research for its ability to slow aging, enhance autophagy, and extend lifespan in multiple species.

An investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors, producing unprecedented weight loss of up to 24% in clinical trials.

An FDA-approved once-weekly GLP-1 receptor agonist for type 2 diabetes with proven cardiovascular benefits and convenient single-use pen delivery.

The first GLP-1 receptor agonist approved for type 2 diabetes, originally derived from Gila monster venom, available in twice-daily and once-weekly formulations.

A highly selective growth hormone-releasing peptide (GHRP) that stimulates GH release with minimal impact on cortisol, prolactin, or appetite, making it the cleanest GHRP available.

An orally active, non-peptide growth hormone secretagogue that mimics ghrelin to raise GH and IGF-1 levels for up to 24 hours per dose, with notable effects on sleep, appetite, and body composition.

An investigational dual glucagon and GLP-1 receptor agonist being developed for obesity and MASH (metabolic dysfunction-associated steatohepatitis) with significant liver fat reduction.

The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.

A modified growth hormone-releasing hormone fragment with a short half-life (~30 minutes) that stimulates pulsatile growth hormone release, closely mimicking the body's natural GH secretion pattern.

A popular clinical combination of two growth hormone secretagogues that work through complementary pathways — GHRH receptor (sermorelin) and ghrelin receptor (ipamorelin) — for synergistic GH release with minimal side effects.

The first 29 amino acids of natural GHRH, previously FDA-approved for pediatric GH deficiency. Now widely used off-label for anti-aging GH optimization as a safer alternative to direct HGH therapy.

A mitochondria-derived peptide that acts as an exercise mimetic, improving metabolic health, insulin sensitivity, and physical performance through AMPK activation.

A short tripeptide bioregulator that targets the pineal gland, supporting melatonin production, sleep quality, and neuroprotection.

A synergistic combination of tesamorelin (GHRH analogue) and ipamorelin (selective GHRP) that amplifies growth hormone release through dual-pathway stimulation, widely considered the gold standard GH peptide stack.

A long-acting growth hormone-releasing hormone (GHRH) analog with a Drug Affinity Complex that extends its half-life to 6-8 days, producing sustained elevated growth hormone and IGF-1 levels.

The pharmaceutical-grade form of Thymosin Alpha-1, FDA-approved in over 30 countries for hepatitis B/C and as an immune modulator for cancer therapy.

An experimental oral growth hormone secretagogue peptide designed to stimulate GH release through the ghrelin receptor, offering a potential alternative to injectable GH-releasing peptides.

A 36-amino acid neuropeptide abundantly expressed in the brain and sympathetic nervous system that regulates appetite, stress resilience, anxiety, and energy homeostasis.